COVID-19 VACCINE UPDATE

2021 ISV VIRTUAL CONGRESS
Feb 10, 2021

Registration
www.ISVCongress.org

CONTACT
PHONE: 1-508-856-1179
EMAIL: Info@ISVCongress.org

Program Feb 10, 8:55am – 11:35am (ET)

8:55am Welcome and Introductions
Chair: Shan Lu, UMass Medical School/ISV
Introduction Linda Klavinskis, King’s College London/ISV

Session One: Adeno Viral Vector Vaccines
Chair: Linda Klavinskis, ISV
9:00am Inna Dolzhikova, Gamaleya National Research Center for Epidemiology and Microbiology
Safety and Efficacy of Sputnik V Vaccine: An Interim Analysis of Phase 3 Trial in Russia
9:30am Sarah Gilbert, Oxford University/AZ
Pandemic Vaccine Development During a Pandemic

Session Two: mRNA Vaccines
Chair: Margaret Liu, ProTherImmune/ISV
10:00am Kathrin Jansen, Pfizer
Efficacy Data Updates from the Pfizer-BioNTech mRNA Vaccine Candidate
10:30am Jacqueline Miller, Moderna
Overview of the Moderna COVID-19 Vaccine (mRNA-1273)

Session Three: Post-Authorization Safety Surveillance
Chair: Shan Lu, ISV
11:00am Tom Shimabukuro, US CDC
COVID-19 Vaccine Safety Update, United States

Wrap up and Future ISV Virtual Congresses
11:30am Shan Lu, ISV

Congress Advisors
Yiwu He, The University of Hong Kong (HKU)
Nick Jackson, The Coalition for Epidemic Preparedness Innovations (CEPI)
Merlin Robb, U.S. Military HIV Research Program (MHRP)
Nina Russel, Bill & Melinda Gates Foundation (BMGF)
Scientific Program
April 28, 8:30 am – 10:20 am (Beijing time)

8:30am Welcome and Introductions
Chair: Shan Lu, U Mass Medical School/ISV
Introduction Denise Doolan, President-Elect ISV

Session One: Adenoviral Vector Based Vaccine
Chair: Denise Doolan, James Cook University/ISV
8:40am Jinbo Gou, CanSino Biological
Updates on Recombinant Adenovirus 5 vector based COVID-19 Vaccine (Ad5-nCoV)

Session Two: Inactivated Vaccines
Chair: Joon Rhee, Chonnam Nat. Uni Med School/ISV
9:10am Meng Li
Sinopharm CNBG
Phase III Study of Inactivated COVID-19 Vaccine
9:40am Weining Meng
Sinovac Biotech Co., Ltd.
Phase III Clinical and Real-World Data of Inactivated COVID-19 Vaccine

Wrap up and Future ISV Virtual Congresses
10:10am Shan Lu, U Mass Medical School/ISV

Congress Advisors
Yiwu He, University of Hong Kong (HKU)
Nick Jackson, Coalition for Epidemic Preparedness Innovations (CEPI)

April 28, 2021
Sydney 10:30 am
Seoul/Tokyo 9:30 am
Beijing 8:30 am
New Delhi 6:30am
Frankfurt 2:30am
London 1:30 am

April 27, 2021
New York 8:30pm
Los Angeles 5:30pm
Scientific Program
May 25, 9:00AM – 11:35AM (EDT)

9:00am Welcome and Introductions
Chair: Shan Lu, U Mass Medical School/ISV
Introduction Linda Klavinskis, King’s College London/ISV

Session One: Adeno Vector COVID-19 Vaccine Update
Chair: Linda Klavinskis, King’s College London/ISV
9:10am Hanneke Schuitemaker, Janssen Vaccines & Prevention B.V.
Janssen’s Effort in the Development of a COVID-19 Vaccine

Session Two: Recombinant Protein COVID-19 Vaccine Update
Chair: Margaret Liu, ProTherImmune/ISV
9:50am Greg Glenn, Novavax, Inc.
COVID-19 Program Update

Session Three: Vaccine Variants
Chair: Shan Lu, U Mass Medical School/ISV
10:30am Pei-Yong Shi, U of Texas Medical Branch
SARS-CoV-2 Variants and Antibody Neutralization

Session Four: Vaccine Safety
Chair: Shan Lu, U Mass Medical School/ISV
11:00am Mariana Castells, Brigham and Women’s Hospital
COVID-19 mRNA Vaccine Safety: Local and Systemic Hypersensitivity

Wrap Up and Future ISV Virtual Congresses
11:30am Margaret Liu, ProTherImmune/ISV

Congress Advisors
Nick Jackson, Coalition for Epidemic Preparedness Innovations (CEPI)

May 25, 2021
New York 9:00 am
Los Angeles 6:00 am
London 2:00 pm
Frankfurt 3:00 pm
Beijing 9:00 pm
Seoul/Tokyo 10:00 pm